New Non-Hormonal Treatment for Menopause Symptoms Recommended by NICE
The National Institute for Health and Care Excellence has recommended fezolinetant as a new non-hormonal treatment option for moderate to severe vasomotor symptoms associated with menopause, including hot flushes and night sweats. Expected to be published in March 2026, the guidance introduces an alternative to hormone replacement therapy (HRT) for women who are unable to take, or prefer not to use, hormonal treatments. This recommendation could expand access to symptom management for a significant number of women across England and support more personalised approaches to menopause care in primary care settings.
Introduction
The National Institute for Health and Care Excellence (NICE) has recommended a new non-hormonal treatment for moderate to severe vasomotor symptoms caused by menopause, including hot flushes and night sweats. Guideline is expected to be published 31st March 26.
Why This Matters
Hot flushes and night sweats are common symptoms during menopause and can significantly affect quality of life.
While hormone replacement therapy (HRT) is commonly used to treat menopausal symptoms, it may not be suitable or preferred for everyone. NICE states that around half a million women in England could be eligible for this new treatment option.
About the Treatment
Fezolinetant is a non-hormonal medicine taken as a daily tablet.
It works by blocking the activity of a specific receptor in the brain that plays a role in regulating body temperature, which helps reduce the hot flushes and night sweats associated with menopause.
Access Through the NHS
Under NICE’s final draft recommendation, fezolinetant will be available on the NHS for women experiencing moderate to severe vasomotor symptoms caused by menopause.
The treatment provides an option for those who cannot take hormone therapy or choose not to use it.
Prescribers should familiarise themselves with MHRA recommendations to minimise risk of liver injury before initiating.
Looking Ahead
The recommendation introduces a new treatment option for managing menopausal symptoms, potentially improving support for many women whose symptoms affect daily life, and has been welcomed by the British Menopause Society
Recent Resources
